TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)
$10.54 0.74 (7.551%)
Analysed TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) News Sources
Telix and Regeneron Announce Strategic Radiopharma Collaboration
12-04-2026
yahoo.com
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus
10-04-2026
yahoo.com
FDA Accepts NDA for TLX101-Px (Pixclara®)
09-04-2026
yahoo.com
Telix Strengthens Board with Additional Director Appointments
08-04-2026
yahoo.com
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline
07-04-2026
yahoo.com
Top European Dividend Stocks To Consider For Your Portfolio
07-04-2026
yahoo.com
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
06-04-2026
yahoo.com
Telix Appoints David Gill as Non-Executive Director
01-04-2026
yahoo.com
ASX Growth Companies With Insider Ownership Up To 38%
26-03-2026
yahoo.com
Telix Pharmaceuticals Eyes 2026 Revenue Near $970M, Highlights PSMA Imaging Growth and Phase III Catalysts
22-03-2026
marketbeat.com
What is the current price of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)?
The current price of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) is $10.54.
TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) since the previous trading day is $0.74.
TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) since the previous trading day is 7.551%.
What is the most recent average sentiment score for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)?
The most recent average sentiment score for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)?
The most recent sentiment for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) is .
SEC-8K** Filing Available For TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.